UNASSIGNED: On 1 January 2019, we implemented Pharmacist-Driven Rapid ART (PHARM-D RAPID ART), including rapid ART initiation by pharmacists. Our retrospective cohort study compared TVS, using a Cox proportional hazards model, and clinical outcomes among individuals with a new HIV diagnosis before (1 January 2017 to 31 December 2017) and after (1 January 2019 to 31 December 2019) implementation.
UNASSIGNED: A total of 108 individuals were included. TVS was significantly shorter (P < .001) for the PHARM-D RAPID ART group (n = 51) compared with the preimplementation group (n = 57) (median: 30 days and 66 days, respectively). Those in the PHARM-D RAPID ART group were significantly more likely to achieve VS at any given time during the study period (adjusted hazard ratio: 3.47 [95% confidence interval, 2.25-5.33]). A total of 94.1% (48/51) of patients in the PHARM-D RAPID ART group were retained in care at 1 year. With a median follow-up of 2.4 years in the PHARM-D RAPID ART group, 98% remained suppressed at last recorded viral load.
UNASSIGNED: A pharmacist-driven model for rapid ART delivery decreases TVS with high rates of retention in care and durable VS. This model could improve clinical outcomes and increase program feasibility and sustainability.
■2019年1月1日,我们实施了药剂师驱动的快速ART(PHARM-DRAPIDART),包括药剂师的快速ART启动。我们的回顾性队列研究比较了TVS,使用Cox比例风险模型,在实施前(2017年1月1日至2017年12月31日)和实施后(2019年1月1日至2019年12月31日)接受新HIV诊断的个体的临床结局.
■共包括108个人。与实施前组(n=57)相比,PHARM-DRAPIDART组(n=51)的TVS显着缩短(P<.001)(中位数:30天和66天,分别)。在研究期间的任何给定时间,PHARM-DRAPIDART组中的人更有可能达到VS(调整后的风险比:3.47[95%置信区间,2.25-5.33]).在PHARM-DRAPIDART组中,共有94.1%(48/51)的患者在1年内被保留在护理中。PHARM-DRAPIDART组的中位随访时间为2.4年,在最后记录的病毒载量时,仍有98%被抑制。
■药剂师驱动的快速ART交付模型降低了TVS,在护理和持久的VS中保留率高。该模型可以改善临床结果,提高项目的可行性和可持续性。